Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease. 2015

Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
Department of Neurology, University of the Saarland, 66421 Homburg/Saar, Germany; German Institute for Dementia Prevention (DIDP), University of the Saarland, 66421 Homburg/Saar, Germany.

Alzheimer's disease (AD) is a neurodegenerative disease characterized by extracellular deposits of amyloid β peptide (Aβ) and microglia-dominated neuroinflammation. The therapeutic options for AD are currently limited. In this study, we investigated the antiinflammatory effects and the underlying molecular mechanisms of Ginkgo biloba extract EGb 761 when administered to TgCRND8 AD mice, which overexpress human Alzheimer's amyloid precursor protein (APP) specifically in neurons. We gave APP-transgenic mice EGb 761 as a dietary supplement for 2 or 5months. Plasma concentrations of EGb 761 components in mice were in the same range as such concentrations in humans taking EGb 761 at the recommended dose (240mg daily). Treatment with EGb 761 for 5months significantly improved the cognitive function of the mice as measured by the Barnes Maze test. It also attenuated the loss of synaptic structure proteins, such as PSD-95, Munc18-1, and SNAP25. Treatment with EGb 761 for 5months inhibited microglial inflammatory activation in the brain. The effects of treatment with EGb 761 for 2months were weak and not statistically significant. Moreover, EGb 761 activated autophagy in microglia. Treatment with EGb 761 decreased Aβ-induced microglial secretion of TNF-α and IL-1β and activation of caspase-1, both of which were abolished by the inhibition of autophagy. Treatment with EGb 761 also reduced the concentrations of NLRP3 protein that colocalized with LC3-positive autophagosomes or autolysosomes in microglia. Additionally, long-term treatment with EGb 761 may reduce cerebral Aβ pathology by inhibiting β-secretase activity and Aβ aggregation. Therefore, long-term treatment with G. biloba extract EGb 761, a clinically available and well-tolerated herbal medication, ameliorates AD pathology by antiinflammatory and Aβ-directed mechanisms.

UI MeSH Term Description Entries
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000076122 Disks Large Homolog 4 Protein A neuronal protein consisting of three PDZ DOMAINS, an SH3 DOMAIN, and a C-terminal guanylate kinase-like region (see MAGUK PROTEINS). It localizes to the POST-SYNAPTIC DENSITY and associates with the cytoplasmic tail of NMDA RECEPTORS and SHAKER POTASSIUM CHANNELS, playing a critical role in NMDA receptor-mediated SYNAPTIC PLASTICITY. Discs Large Homolog 4 Protein,PSD-95 Protein,PSD95 Protein,Postsynaptic Density Protein 95,SAP-90 Protein,SAP90 Protein,Synapse-Associated Protein 90,PSD 95 Protein,SAP 90 Protein,Synapse Associated Protein 90
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D050825 Synaptosomal-Associated Protein 25 A ubiquitous target SNARE protein that interacts with SYNTAXIN and SYNAPTOBREVIN. It is a core component of the machinery for intracellular MEMBRANE FUSION. The sequence contains 2 SNARE domains, one is the prototype for the Qb-SNARES, and the other is the prototype for the Qc-SNARES. SNAP-25 Protein,SNAP-25B Protein,SNAP25 Protein,SNAP 25 Protein,SNAP 25B Protein,Synaptosomal Associated Protein 25

Related Publications

Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
January 2003, Drugs in R&D,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
July 2007, Current Alzheimer research,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
January 2004, Current pharmaceutical design,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
September 1986, Presse medicale (Paris, France : 1983),
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
January 1994, Methods in enzymology,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
September 2014, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
July 2002, Hearing research,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
May 1995, Biochemical pharmacology,
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
January 1992, Wiener medizinische Wochenschrift (1946),
Xu Liu, and Wenlin Hao, and Yiren Qin, and Yann Decker, and Xuan Wang, and Martin Burkart, and Karl Schötz, and Michael D Menger, and Klaus Fassbender, and Yang Liu
December 2007, Pharmacological research,
Copied contents to your clipboard!